Literature DB >> 32716760

Pembrolizumab-Induced Bullous Pemphigoid Treated With Rituximab.

Pritha Sharma1, Martin Barnes1, Shaha Nabeel1, William LiPera2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32716760     DOI： 10.1200/JOP.19.00751

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN： 2688-1527


× No keyword cloud information.
  3 in total

Review 1.  Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Authors:  Chieh-Hsun Chen; Hsin-Su Yu; Sebastian Yu
Journal:  Curr Oncol       Date:  2022-04-18       Impact factor: 3.109

2.  Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report.

Authors:  Tulika Chatterjee; Thomas F Rashid; Salman B Syed; Moni Roy
Journal:  Cureus       Date:  2022-01-31

3.  Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Authors:  Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Journal:  Dermatopathology (Basel)       Date:  2022-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.